May 9th 2025
Poor API quality may often lead to delays in production and a shortage of supply.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Understanding ICH Q11—FDA's Guidance on the Development and Manufacture of Drug Substances
May 2nd 2013The author provides a review of FDA's guidance document, Guidance for Industry: Q11 Development and Manufacture of Drug Substances, and its relation to the International Conference on Harmonization's Q11 document and its application to the industry.
Big Pharma's Manufacturing Investments in Biologics
May 1st 2013Despite overall manufacturing rationalization in the pharmaceutical/biopharmaceutical industry, the large pharmaceutical companies continue to invest in biologic-based manufacturing. The author provides an update in recent investment activity among the pharmaceutical majors in biologic-drug substance, vaccine, and parenteral drug manufacturing.
Catalent Biologics Opens New Single-Use Biomanufacturing Facility in Madison
April 26th 2013Catalent Pharma Solutions, a provider of drug and biologic development services, delivery technologies and supply solutions, has officially opened a new biomanufacturing center of excellence in Madison. The facility, which was constructed in response to customer demand, is expected to quadruple Catalent's current biologics manufacturing capacity and extensively utilise single-use technology for greater flexibility and efficiency. It will allow the company to extend its offerings in the biologics sector while enhancing the efficiency and output of its proprietary GPEx cell line engineering technology as well as other mammalian cell lines.
BioOutsource Opens New Facility in Cambridge, Massachusetts
April 24th 2013BioOutsource, a contract testing services provider to the biopharmaceutical industry, has opened a new facility in Cambridge, Massachusetts. The facility marks the company's first North American offices, which were opened in response to increasing demand for the company's bioanalytical and biosafety services, particularly in the field of biologic and biosimilar characterisation.
EMA Upgrades Database to Strengthen Supply Chain Security
April 23rd 2013EMA has upgraded its EudraGMP database to include information on GDP in addition to GMP. The new EudraGMDP database is a key deliverable of the Falsified Medicines Directive (FMD) that came into effect in January 2013. The aim is to increase supply chain security in the EU by making supervision of manufacturing and distribution of medicines more robust to ensure supplier compliance.
PDA Supply Chain Conference Preview
April 12th 2013Mary Storch, a member of the planning PDA supply chain committee, is associate director, external QA oversight, for Ben Venue Laboratories. She discusses parenteral drug-supply chain challenges, in terms of the complexity of the raw materials supplied as well as additional consideration in end-product distribution, such as cold-chain requirements.